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Cancer screening programs have been highly successful at reducing morbidity and mortality due to 
screening-preventable or treatable cancers.  Such programs, however, also carry the risk of 
detecting cancers that would never have become symptomatic or clinically apparent without 
screening.  As they would not pose a risk to the patient, the identification and unnecessary treatment 
of such indolent or slow growing tumors can potentially lead to both individual and systemic 
harms.  One type of cancer in which such overdiagnosis can be problematic is prostate 
cancer.  Under the direction of Dr. Ruth Etzioni in the Public Health Sciences Division, Mr. Roman 
Gulati and colleagues developed a clinical tool to help inform patients with screen-detected prostate 
cancer of the chance their cancer was overdiagnosed, which may be helpful for guiding treatment 
decisions.  This work was reported in a recent issue of the Journal of the National Cancer Institute.  
Overdiagnosis is a serious issue, says senior author Etzioni, as "in the United States, about one in 
four to one in three men detected by prostate-specific antigen (PSA) screening is 
overdiagnosed."  However, the chance than an individual case has been overdiagnosed can vary 
widely.  Unfortunately, "men with screen-detected prostate cancers are making treatment decisions 
with only limited information about the chance that their cancer is overdiagnosed," says lead author 
Gulati, which makes it difficult to weigh the likely harms and benefits of different treatment 
options.  In order to give patients this information, the authors first developed a novel mathematical 
simulation model of prostate cancer natural history (see other references below).  This model 
provides "a reasonable reflection of what would have happened to screen-detected cases had they 
not been treated," says Etzioni, and "is what we need to know to calculate the chance of 
overdiagnosis." 
The authors used this framework to predict the individualized risk of overdiagnosis among non-
metastatic patients diagnosed by screening with a PSA less than 10 ng/mL, given the patient’s age, 
Gleason score, and PSA at diagnosis.  Each of these factors was important for determining the 
chances of overdiagnosis, which ranged from 2.9% to 88.1% (see figure).  Age was the most 
important factor, since overdiagnosis is highly dependent on remaining life expectancy.  Each  
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additional year of age at diagnosis was associated with a 12.9% increase in the odds of 
overdiagnosis.  For the other factors, each additional 1 ng/mL of serum PSA (up to 10 ng/mL) was 
associated with a 16.6% decrease in the odds of overdiagnosis, while a Gleason score of 7 or more 
(compared to 6 or less) was associated with a 19.5% decrease in the odds of 
overdiagnosis.  Together, the model predicts the risk of overdiagnosis among PSA-detected patients 
reasonably accurately, with an area under the curve of 0.75.  
Says Gulati, "we present this information in the form of a nomogram so that patients can better 
understand their personalized risk of overdiagnosis."  This nomogram allows an easy calculation of 
the overall chance of overdiagnosis given these individual patient characteristics.  Such information 
could be useful for patients making treatment decisions following a screen-detected diagnosis.  For 
patients with a very high chance of overdiagnosis, says Etzioni, "perhaps our results can help these 
cases feel more comfortable with an active surveillance approach." 
While this tool is a valuable resource, the authors are working towards refining these predictions 
further.  "We intend to improve the nomogram by incorporating patient comorbidities and additional 
tumor staging information," said Gulati.  Furthermore, additional work in small patient groups may 
help identify how to most clearly communicate this information to patients.  Given their success in 
prostate cancer, the authors are also working to develop a similar tool for breast cancer detected in 
women undergoing mammography screening.  As with prostate cancer, the goal remains the same, 
says Etzioni: "to package these results into an educational aid for patients at risk of overdiagnosis, 
so that they can fully participate in shared and informed decision-making regarding their care." 
Other PHS investigators contributing to this project were Drs. Lurdes Inoue, John Gore, and Jeffrey 
Katcher. 
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(Image provided by Mr. Roman Gulati) 
Plot showing the chance that a prostate-specific antigen (PSA) screening-detected prostate cancer 
given a patient’s age (x-axis), PSA (color gradient), and Gleason score (6 or less (A) versus 7 or 
more (B)), among non-metastatic men with PSA less than 10 ng/mL. 
 
